Mr. Speaker, that is precisely what I suggest the member do: make the necessary changes and ask good questions at committee. I am convinced that the members from all the parties represented in this place can do that.
I agree with him. When the minister's discretionary power is too broad, that does open the door to all kind of lobbying, especially from big firms seeking to influence the minister's decision. And pharmaceutical companies are no small potatoes.
Unfortunately for me and for the hon. member, there will always be lobbyists; we just have to learn to live with them. One thing is for sure, though: making the nature of future regulations governing drug advertising very clear in the bill will ensure that the minister will not necessarily be able to do as he pleases when he pleases and, more importantly, he will not have pressure put on him or take orders from lobbies which might be richer or more influential.